Skip to content
HowShorted

Cidara Therapeutics, Inc. short interest in 2025

In 2025, Cidara Therapeutics, Inc.'s disclosed short interest ran from 1.54% of shares outstanding on 15 Jan 2025 to 5.99% on 31 Dec 2025, a change of +4.45 percentage points. The year's high was 20.68% on 15 Jul 2025 and its low 1.54% on 15 Jan 2025, averaging 7.70% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 5.16 days on 29 Aug 2025. Full history: Cidara Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025

Aggregate net short position time series for Cidara Therapeutics, Inc. in 2025

2025 in figures

Start of year
1.54% (15 Jan 2025)
End of year
5.99% (31 Dec 2025)
Change
+4.45 pp
High
20.68% (15 Jul 2025)
Low
1.54% (15 Jan 2025)
Average
7.70%
Highest days to cover
5.16 (29 Aug 2025)
SEC filings marked
8

Every report in 2025

Cidara Therapeutics, Inc. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 20251.54%1.00
31 Jan 20251.96%1.43
14 Feb 20252.58%1.77
28 Feb 20252.17%2.20
14 Mar 20252.65%3.1810-K filed, results (8-K)
31 Mar 20254.29%2.45
15 Apr 20254.38%2.12
30 Apr 20254.13%4.83
15 May 20254.07%4.3310-Q filed, results (8-K)
30 May 20254.33%2.27
13 Jun 20255.92%2.94
30 Jun 202514.69%1.00
15 Jul 202520.68%2.67
31 Jul 202519.96%3.94
15 Aug 20258.21%4.6710-Q filed, results (8-K)
29 Aug 20258.48%5.16
15 Sep 20258.65%3.88
30 Sep 202512.01%2.11
15 Oct 202511.76%2.78
31 Oct 202512.63%3.74
14 Nov 202510.49%1.4810-Q filed, results (8-K)
28 Nov 20256.73%1.04
15 Dec 20256.42%1.92
31 Dec 20255.99%2.23

See also: Cidara Therapeutics, Inc.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.